跳至主要内容
临床试验/NCT05318274
NCT05318274进行中(未招募)不适用

Hypofractionated Radiation Therapy (1 Week) Compared With Standard Treatment (3.1 Weeks), Evaluation of Local Control of Breast Cancer Treated With Conservative Surgery.

Coordinación de Investigación en Salud, Mexico1 个研究点 分布在 1 个国家目标入组 72 人开始时间: 2021年4月26日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
72
试验地点
1
主要终点
Identify the recurrence timing.

研究概览

简要总结

An explanatory study comparing complementary treatment to breast conservative surgery with radiation therapy DCIS, T1-T2 N0 M0 (AJCC v8) 1 week schedule vs 3.1 weeks standard schedule, in order to determine the equivalence of local tumor control, survival, acute and chronic toxicity. Shorter curse of radiation therapy may lead to similar local control of tumor cells and lower rates of toxicity than 3.1 standard treatment.

详细描述

PRIMARY OBJECTIVE:

I. Compare the effectiveness of hypofractionated radiotherapy (1 week) with standard treatment (3.1 weeks) in the local control of breast cancer treated with conservative surgery.

SECONDARY OBJECTIVES:

I. Identify the histological lineage of the tumor.

II. Identify the degree of differentiation of tumor cells.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Patients diagnosed by histopathological report of ductal carcinoma in situ (DCIS) or invasive breast carcinoma.
  • Treated with breast-conserving surgery and stage pT1-2 pN0 M
  • Over 18 years.
  • Patients who sign informed consent for research study.

排除标准

  • Positive nodes.
  • Clinical or pathological stage T3-T
  • History of previous irradiation.
  • Postoperative positive margin.

结局指标

主要结局

Identify the recurrence timing.

时间窗: 5 years

Quantify the time to recurrence through follow up in both groups

Identify the progression timing.

时间窗: 5 years

Quantify the time to progression through follow up in both groups

次要结局

  • Identify the presence and type of receptors (estrogen, progesterone, HER-2NEU) through immunohistochemistry(14 months)
  • Identify the degree of differentiation of tumor cells(14 months)
  • Measure the frequency of toxicity in both groups.(5 years)
  • Classify toxicity according to its severity.(5 years)
  • Identify the histological lineage of the tumor(14 Months)

研究者

发起方
Coordinación de Investigación en Salud, Mexico
申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Patricia Berenice Bolado Garcia

MD.

Coordinación de Investigación en Salud, Mexico

研究点 (1)

Loading locations...

相似试验